Department of Medical Oncology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey.
J BUON. 2020 Mar-Apr;25(2):1063-1069.
We aimed to investigate the prognostic significance of neutrophil/lymphocyte ratio (NLR), an indirect indicator for the immune response and AST/ALT ratio (De Ritis), liver enzymes that are commonly used in various clinical fields, in patients with advanced-stage pancreatic cancer.
NLR and De Ritis of the patients with diagnosis of locally advanced and metastatic pancreatic cancer between the 2010-2017 were evaluated retrospectively. All patients were divided into two groups as high and low according to NLR and De Ritis cut-off values which were 2.4 and 0.75, respectively.
A total of 191 patients were evaluated. The mean overall survival (OS) in patients with NLR<2.4 at the time of diagnosis was 10±0.8 months, while it was 4±0.49 months in patients with NLR>2.4 (p<0.0001). The mean OS of the patients with a De Ritis <0.75 was 8±1.2 months, whereas the survival of those with De Ritis >0.75 was 6±0.74 months (p=0.024). The mean progression free survival (PFS) in patients with NLR<2.4 and De Ritis <0.75 at diagnosis were 5±0.76 months and 6±0.87 months respectively, whilst it was 3±0.37 months in patients with NLR>2.4 (p=0.017) and 4±0.3 months in patients with De Ritis >0.75 (p=0.14).
The NLR and De Ritis are associated with prognosis in many cancers and have been found to be associated with survival outcome in advanced-stage pancreatic cancer patients.
我们旨在研究中性粒细胞/淋巴细胞比值（NLR）作为免疫反应的间接指标和天冬氨酸转氨酶/丙氨酸转氨酶比值（De Ritis），这两种酶在各种临床领域中常用，在晚期胰腺癌患者中的预后意义。
回顾性评估了 2010 年至 2017 年间诊断为局部晚期和转移性胰腺癌的患者的 NLR 和 De Ritis。根据 NLR 和 De Ritis 的截止值（分别为 2.4 和 0.75），将所有患者分为高值和低值两组。
共评估了 191 例患者。诊断时 NLR<2.4 的患者的总生存（OS）平均值为 10±0.8 个月，而 NLR>2.4 的患者为 4±0.49 个月（p<0.0001）。De Ritis<0.75 的患者的平均 OS 为 8±1.2 个月，而 De Ritis>0.75 的患者的生存时间为 6±0.74 个月（p=0.024）。诊断时 NLR<2.4 和 De Ritis<0.75 的患者的中位无进展生存（PFS）分别为 5±0.76 个月和 6±0.87 个月，而 NLR>2.4 的患者为 3±0.37 个月（p=0.017），De Ritis>0.75 的患者为 4±0.3 个月（p=0.14）。
NLR 和 De Ritis 与许多癌症的预后相关，并且已经发现与晚期胰腺癌患者的生存结局相关。
